Lisdexamfetamine Dimesylate is a prescription medication that acts on the central nervous system, primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 and above, as well as Binge Eating Disorder (BED) in adults. The drug metabolizes to release dextroamphetamine, which regulates dopamine and norepinephrine levels in the brain, enhancing focus and behavioral control.
Its molecular structure is specially designed to slow the release of its effects, reducing abuse potential. In the treatment of BED, it effectively decreases the frequency of binge episodes and improves patients' mood and quality of life. It is classified as a Schedule II controlled substance, and strict adherence to medical instructions is required.
The generic name of this medication is "Lisdexamfetamine Dimesylate," with the primary brand name being Vyvanse. Different countries may have other brand names, but the generic name and active ingredient remain consistent. When purchasing, verify the generic name and controlled substance label on the packaging.
This medication is classified as a "Central Nervous System Stimulant" and is also a Schedule II controlled substance. Its mechanism of action differs from other ADHD medications such as methylphenidate but falls within the stimulant category.
Mild side effects may include: dry mouth, insomnia, decreased appetite, headache. About 10-20% of patients may experience these symptoms, which usually resolve as the body adapts to the medication.
Seek immediate medical attention for serious side effects:
Contraindications: Patients with cardiovascular disease, severe hypertension, severe anxiety disorders, or hypersensitivity to amphetamines should not use this medication. Patients with a history of heart disease or sudden death in the family should be carefully evaluated.
Use during pregnancy and breastfeeding requires strict medical supervision, as it may affect fetal development or be excreted in breast milk. Use in patients under 18 for BED should be carefully assessed for risks and benefits.
Combining with monoamine oxidase inhibitors (MAOIs) may induce hypertensive crises; a 14-day interval is required. Concurrent use with antidepressants (such as SSRIs) may increase anxiety symptoms. Avoid combining with caffeine-containing beverages, as it may enhance stimulant effects.
Initial dose for ADHD is typically 30-70 mg/day, taken once in the morning. For BED, the starting dose is 30 mg/day, titrated up to a maximum of 60-70 mg. Dose adjustments should be made by a physician based on response and side effects.
Swallow whole; do not chew or crush. Can be taken with or without food, on an empty stomach or with a light meal. If a dose is missed and the next dose is close, skip the missed dose and take the next as scheduled; do not double the dose.
If a dose is missed within 1-2 hours of the scheduled time, take it immediately. If close to the next dose, skip the missed dose and resume the regular schedule. Do not increase the dose to compensate for missed doses.
Overdose may cause hyperthermia, seizures, respiratory difficulties, and life-threatening symptoms. If overdose is suspected, seek immediate medical attention:
Now, I will generate 5 FAQs about Lisdexamfetamine Dimesylate (dextroamphetamine dimesylate) in Traditional Chinese, ensuring all formatting and content requirements are met. These FAQs will focus on practical information such as medication timing, side effect management, drug interactions, use during pregnancy, and long-term dependency risks. Each question will be unique and cover different aspects, avoiding overlap with the main article content. The answers will be concise, 3-4 sentences, accurate, and use proper medical terminology. All content will be in Traditional Chinese, with correct HTML tags, and formatted as per the example provided.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
